Legal entity
All 1 tracked stories fall under one category: regulation. Food and Drug Administration is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 6.5 in the same window.
Last mentioned: Mar 16, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Food and Drug Administration is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 6.5 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 3.5 for the same window. Vinay Prasad appears in 1 tracked Legal story from March 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 44 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vinay Prasad. Shared-story counts are live from our verified record — not editorial picks.
Refusal to File
FDA's Vinay Prasad issues a formal refusal to review the flu vaccine application.
Grant Rescissions
The White House rescinds hundreds of millions in mRNA research funding.
Workaround Support
FDA officials reportedly signal acceptance of Moderna's alternative trial data submission.
Flu Vaccine Collaboration
Moderna begins working with the FDA on trial designs for its mRNA flu vaccine.
Peak Valuation
Moderna reaches a $200 billion market cap following global vaccine success.
The FDA's rare 'refusal to file' regarding Moderna's mRNA flu vaccine signals a pivot from pandemic-era collaboration to a more adversarial regulatory environment. This unpredictability, combined with rescinded federal grants and a 90% decline in market value, highlights the growing legal and compliance risks for biotech firms.
Source: Michael Sohn (us) · Michael Sohn (us)
Vinay Prasad is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
